boniva and Alimta Interactions

Interactions between boniva(ibandronate) and Alimta (pemetrexed)

pemetrexed and ibandronate (Moderate Drug-Drug)

MONITOR: Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.

MANAGEMENT: Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous bisphosphonates, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy. Pemetrexed should not be administered to patients whose creatinine clearance is below 45 mL/min.